Home » Archives for Rosemarie Gant » Page 8 Girard N, Wolf J, Kron A, Scheffler M, Knott CS Bosquet L et al. Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth...
Home » Archives for Rosemarie Gant » Page 8 Kearney M, Knott CS, Mahmoudpour H, Verpillat P. Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England. ESMO 2022; 2022 Sept...
Home » Archives for Rosemarie Gant » Page 8 Mahmoudpour H, Knott CS, Amin A, Boutmy E, Verpillat P. Evolution of the treatment landscape in patients with advanced or metastatic cancers following the approval of immuno-oncology treatments: analysis of the England...
Home » Archives for Rosemarie Gant » Page 9 Goulden S, Heffernan K, Nikitas FS, Shukla U, Knott CS, Hunger M, Pahwa A, Schade R. Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent (A/R)...
Home » Publications » Published 2022 Clements K, Dodwell D, Hilton B, Stevens-Harris I, Pinder S, Wallis MG, et al.BMJ Open 2022;12: e061585. http://dx.doi.org/10.1136/bmjopen-2022-061585corr1 Abstract: Purpose The introduction of breast screening in the UK led to an...
Home » Publications » Published 2022 Angela Whittle, Betina Blak, Amy Zalin-Miller, Orlaith Condon (2022) ‘Characteristics, treatment patterns and outcomes of patients with newly diagnosed advanced ovarian cancer (aOC) in England’; abstract accepted at the European...